

Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

November 21, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 21, 2023-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 1:20 pm ET in Miami, FL.

A webcast from the fireside chat will be available on the "Events & Presentations" section of the Company's website at www.kezarlifesciences.com. Following the event, an archived webcast will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel treatments for immune-mediated and oncologic disorders. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated in a Phase 2b clinical trial for lupus nephritis and a Phase 2a clinical trial for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. Kezar's oncology product candidate, KZR-261, targeting the Sec61 translocon and protein secretion pathway, is being evaluated in an open-label dose-escalation Phase 1 clinical trial to assess safety, tolerability and preliminary tumor activity in solid tumors. For more information, visit www.kezarlifesciences.com, and follow us on LinkedIn, Facebook, Twitter and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231121698956/en/

Investor Contact: Gitanjali Jain Vice President, Investor Relations and External Affairs Kezar Life Sciences, Inc. giain@kezarbio.com

Media Contact: Will Zasadny Evoke Canale will.zasadny@evokegroup.com

Source: Kezar Life Sciences, Inc.